Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021294 · ClinicalTrials.gov registry record · Phase 2
Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis
A Phase 2 study, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00021294 is a Phase 2 study that has completed, run by University of Arizona.
The verdict
NCT00021294, a Phase 2 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Eflornithine with or without triamcinolone may be effective in preventing nonmelanoma skin cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of eflornithine with or without triamcinolone in preventing nonmelanoma skin cancer in patients who have actinic keratosis.
Interventions
- DRUG eflornithine
- DRUG triamcinolone
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-05 |
| Est. Completion | 2002-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00021294
The ClinicalTrials.gov registry entry for NCT00021294 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which eflornithine is the first listed.
NCT00021294 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00021294 about?
NCT00021294 is a clinical study titled "Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Eflornithine with or without triamcinolone may be effective in preventing nonmelanoma skin cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of eflornithin...
What is the current status of trial NCT00021294?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-05. Estimated completion is 2002-06.
What interventions are being tested in trial NCT00021294?
The interventions under investigation include: eflornithine (DRUG), triamcinolone (DRUG).
Who is sponsoring clinical trial NCT00021294?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.